OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test
BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
COVID-19
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in...
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
Bentrio USA Altamira Therapeutics Re-launches Bentrio in Europe for Allergic RhinitisHAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM...
WIMI Hologram Academy: The Application of Virtual Reality technology in pulmonary function rehabilitation in COVID-19 patients
HONG KONG, Sept. 27, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working...
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports...
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John...
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively...
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing...
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine ResearchPRINCETON, N.J.,...
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered...
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on...
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration
September 29, 2022 @ 8 AM ETLangham Hotel, NYC LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP)...
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta)...
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...
Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer
TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...